1269754-98-4

Usage

Uses

Used in Pharmaceutical Synthesis:
(S)-1-(Tetrahydro-2H-pyran-4-YL)ethanamine is used as an intermediate in the pharmaceutical industry for the synthesis of various drugs and organic compounds. Its unique structure allows for the creation of a wide range of molecules with different therapeutic properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (S)-1-(Tetrahydro-2H-pyran-4-YL)ethanamine is used as a building block for designing and developing new drugs. Its tetrahydropyran ring and ethylamine side chain can be modified to create novel molecules with potential therapeutic applications.
Used in Drug Discovery:
(S)-1-(Tetrahydro-2H-pyran-4-YL)ethanamine is also utilized in drug discovery processes. Its structural features make it a valuable candidate for the development of new pharmaceutical agents, as it can be modified to target specific biological pathways or receptors.
Used in Biological Research:
Due to its potential biological activity, (S)-1-(Tetrahydro-2H-pyran-4-YL)ethanamine may be of interest for further research and development in biological studies. Its unique structure could provide insights into new mechanisms of action or interactions with biological systems, potentially leading to the discovery of new therapeutic approaches.

Upstream product

• 137052-08-5 1-(tetrahydro-2H-pyran-4-yl)ethan-1-one 
• 1269756-02-6 (1S)-1-(oxan-4-yl)ethanamine hydrochloride 
• 1269755-00-1 (R)-2-methyl-N-[(1S)-1-(oxan-4-yl)ethyl]propane-2-sulfinamide 
• 1269754-99-5 (R,E)-2-methyl-N-((tetrahydro-2H-pyran-4-yl)methylidene)propan-2-sulfinamide 
• 50675-18-8 3,4,5,6-tetrahydro-2H-pyran-4-carbaldehyde 

Downstream Products

• 2088113-98-6 6-[6-(methoxymethyl)-3-pyridinyl]-4-{[(1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl]amino}-3-quinolinecarboxamide 

Relevant academic research and scientific papers

CINNOLIN-4-AMINE COMPOUNDS AND THEIR USE IN TREATING CANCER

This specification generally relates to compounds of Formula (I). And pharmaceutically acceptable salts thereof, where R1, R2 and R3 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts thereof; kits comprising such compounds and salts thereof; methods of manufacture of such compounds and salts thereof; intermediates useful in the manufacture of such compounds and salts thereof; and to methods of treating ATM kinase mediated disease, including cancer, using compounds of Formula (I) and salts thereof alone or in combination with other therapies.

PHENYL-HETEROARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I, and pharmaceutical compositions comprising such compounds

3-(AMINOARYL)-PYRIDINE COMPOUNDS

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are pharmaceutical compositions containing these compounds and methods of treating a disease or condition mediated by CDK9 using these compounds and compositions.

PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a pyrimidine compound of formula (I): wherein one of X and Y but not both is N, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tantomers, diastereomers, deuterated versions, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds

N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES

The present invention provides a compound of general formula:wherein Z2-Z6 include one or two nitrogen atoms as described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a compound of the general formula (1): wherein one of X and Y is N and the other is an optionally substituted carbon atom, and Z2-Z5 represent one or two nitrogen atoms, as further described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals and as components of pharmaceutical compositions. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds described herein or pharmaceutical compositions comprising such compounds.

PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

HETEROARYL COMPOUNDS AS KINASE INHIBITORS

The present invention provides a compound of Formula (I): and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor

PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The present invention provides a compound of Formula (I) and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor.